Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection

Autores
Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; Spence, David Warren; Hardeland, Rudiger; Pandi Perumal, Seithikurippu R.
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Srinivasan, Uddanapalli S.. No especifíca;
Fil: Kaur, Charanjit. No especifíca;
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Hardeland, Rudiger. Universität Göttingen; Alemania
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Materia
AGOMELATINE
INSOMNIA
LIGHT THERAPY
MELATONIN
OXIDATIVE STRESS
PARKINSON'S DISEASE
RAMELTEON
REM SLEEP BEHAVIOR DISORDER
TASIMELTEON
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/192174

id CONICETDig_e729548378918656698884d90ff114e3
oai_identifier_str oai:ri.conicet.gov.ar:11336/192174
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotectionSrinivasan, VenkatramanujamCardinali, Daniel PedroSrinivasan, Uddanapalli S.Kaur, CharanjitBrown, Gregory M.Spence, David WarrenHardeland, RudigerPandi Perumal, Seithikurippu R.AGOMELATINEINSOMNIALIGHT THERAPYMELATONINOXIDATIVE STRESSPARKINSON'S DISEASERAMELTEONREM SLEEP BEHAVIOR DISORDERTASIMELTEONhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.Fil: Srinivasan, Venkatramanujam. No especifíca;Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Srinivasan, Uddanapalli S.. No especifíca;Fil: Kaur, Charanjit. No especifíca;Fil: Brown, Gregory M.. University of Toronto; CanadáFil: Spence, David Warren. No especifíca;Fil: Hardeland, Rudiger. Universität Göttingen; AlemaniaFil: Pandi Perumal, Seithikurippu R.. No especifíca;SAGE Publications2011-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/192174Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-3171756-2864CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1177/1756285611406166info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756285611406166info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:42Zoai:ri.conicet.gov.ar:11336/192174instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:42.345CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
title Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
spellingShingle Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
Srinivasan, Venkatramanujam
AGOMELATINE
INSOMNIA
LIGHT THERAPY
MELATONIN
OXIDATIVE STRESS
PARKINSON'S DISEASE
RAMELTEON
REM SLEEP BEHAVIOR DISORDER
TASIMELTEON
title_short Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
title_full Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
title_fullStr Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
title_full_unstemmed Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
title_sort Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
dc.creator.none.fl_str_mv Srinivasan, Venkatramanujam
Cardinali, Daniel Pedro
Srinivasan, Uddanapalli S.
Kaur, Charanjit
Brown, Gregory M.
Spence, David Warren
Hardeland, Rudiger
Pandi Perumal, Seithikurippu R.
author Srinivasan, Venkatramanujam
author_facet Srinivasan, Venkatramanujam
Cardinali, Daniel Pedro
Srinivasan, Uddanapalli S.
Kaur, Charanjit
Brown, Gregory M.
Spence, David Warren
Hardeland, Rudiger
Pandi Perumal, Seithikurippu R.
author_role author
author2 Cardinali, Daniel Pedro
Srinivasan, Uddanapalli S.
Kaur, Charanjit
Brown, Gregory M.
Spence, David Warren
Hardeland, Rudiger
Pandi Perumal, Seithikurippu R.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv AGOMELATINE
INSOMNIA
LIGHT THERAPY
MELATONIN
OXIDATIVE STRESS
PARKINSON'S DISEASE
RAMELTEON
REM SLEEP BEHAVIOR DISORDER
TASIMELTEON
topic AGOMELATINE
INSOMNIA
LIGHT THERAPY
MELATONIN
OXIDATIVE STRESS
PARKINSON'S DISEASE
RAMELTEON
REM SLEEP BEHAVIOR DISORDER
TASIMELTEON
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Srinivasan, Uddanapalli S.. No especifíca;
Fil: Kaur, Charanjit. No especifíca;
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Hardeland, Rudiger. Universität Göttingen; Alemania
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
description Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
publishDate 2011
dc.date.none.fl_str_mv 2011-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/192174
Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-317
1756-2864
CONICET Digital
CONICET
url http://hdl.handle.net/11336/192174
identifier_str_mv Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-317
1756-2864
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1177/1756285611406166
info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756285611406166
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269418724261888
score 13.13397